| Steven Alexander Beim, MD | |
|
1205 S Austin St, Brenham, TX 77833-4575 | |
| (979) 251-9990 | |
| (979) 251-7003 |
| Full Name | Steven Alexander Beim |
|---|---|
| Gender | Male |
| Speciality | Ophthalmology |
| Experience | 34 Years |
| Location | 1205 S Austin St, Brenham, Texas |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1629075437 | NPI | - | NPPES |
| 112003201 | Medicaid | TX | |
| 76-0602649 | Other | TX | FEDERAL TAX IDENTIFICATIO |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207W00000X | Ophthalmology | J8909 (Texas) | Primary |
| Entity Name | Steven A. Beim, M.d., P.a. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487874285 PECOS PAC ID: 7416945522 Enrollment ID: O20040505001167 |
News Archive
For the first time, researchers have been able to identify effective treatments for patients with rare cancers by analyzing genes and proteins in their blood and tumors. In a study reported in The Oncologist, half the patients receiving these targeted treatments saw their rare cancers either stabilize, shrink or go into remission.
Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced OICR is investing $4.6 million over two years in PanCuRx, an initiative that seeks solutions to the high fatality rate of pancreatic cancer.
U.S. Army service members are increasingly deployed in regions of the world where tuberculosis (TB) is rampant, such as Iraq and Afghanistan, and the military now faces a growing medical problem. But it is not TB itself that is on the rise-instead, the problem lies with the growing number of "pseudoepidemics," or clusters of false-positives for TB that are the result of universal testing with a notoriously inaccurate tuberculin skin test (TST) and inconsistent procedures for interpreting those tests in low-risk populations.
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
› Verified 9 days ago
| Entity Name | Health And Human Services Commission |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1356414692 PECOS PAC ID: 2163795824 Enrollment ID: O20170908001058 |
News Archive
For the first time, researchers have been able to identify effective treatments for patients with rare cancers by analyzing genes and proteins in their blood and tumors. In a study reported in The Oncologist, half the patients receiving these targeted treatments saw their rare cancers either stabilize, shrink or go into remission.
Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced OICR is investing $4.6 million over two years in PanCuRx, an initiative that seeks solutions to the high fatality rate of pancreatic cancer.
U.S. Army service members are increasingly deployed in regions of the world where tuberculosis (TB) is rampant, such as Iraq and Afghanistan, and the military now faces a growing medical problem. But it is not TB itself that is on the rise-instead, the problem lies with the growing number of "pseudoepidemics," or clusters of false-positives for TB that are the result of universal testing with a notoriously inaccurate tuberculin skin test (TST) and inconsistent procedures for interpreting those tests in low-risk populations.
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Steven Alexander Beim, MD 1205 S Austin St, Brenham, TX 77833-4575 Ph: (979) 251-9990 | Steven Alexander Beim, MD 1205 S Austin St, Brenham, TX 77833-4575 Ph: (979) 251-9990 |
News Archive
For the first time, researchers have been able to identify effective treatments for patients with rare cancers by analyzing genes and proteins in their blood and tumors. In a study reported in The Oncologist, half the patients receiving these targeted treatments saw their rare cancers either stabilize, shrink or go into remission.
Dr. Tom Hudson, President and Scientific Director of the Ontario Institute for Cancer Research (OICR) today announced OICR is investing $4.6 million over two years in PanCuRx, an initiative that seeks solutions to the high fatality rate of pancreatic cancer.
U.S. Army service members are increasingly deployed in regions of the world where tuberculosis (TB) is rampant, such as Iraq and Afghanistan, and the military now faces a growing medical problem. But it is not TB itself that is on the rise-instead, the problem lies with the growing number of "pseudoepidemics," or clusters of false-positives for TB that are the result of universal testing with a notoriously inaccurate tuberculin skin test (TST) and inconsistent procedures for interpreting those tests in low-risk populations.
A Food and Drug Administration (FDA) panel yesterday recommended the approval of Orexigen Therapeutics' weight loss drug Contrave. This is the first time a weight loss drug has received the nod. The vote went 13 to 7 for Contrave's approval and 11 to 8, with an abstention that additional studies be conducted on heart risks. Although experts agree to risks they believe the benefits outweigh the risks. Although the FDA is not compelled to go with the panel's recommendation, it more often than not does. The FDA will deliver its verdict by Jan. 31 2011.
› Verified 9 days ago
Rachel B Cook, M.D. Ophthalmology Medicare: Accepting Medicare Assignments Practice Location: 605 Medical Ct Ste 203, Brenham, TX 77833 Phone: 979-830-1444 Fax: 979-830-1866 | |
Dr. Peter G Amaral, M.D. Ophthalmology Medicare: Not Enrolled in Medicare Practice Location: 635 Medical Pkwy, Brenham, TX 77833 Phone: 979-830-1444 Fax: 979-830-1866 | |
Cheryl Joan Horton, MD Ophthalmology Medicare: May Accept Medicare Assignments Practice Location: 1102 Hwy 290w, Brenham, TX 77833 Phone: 979-836-9811 Fax: 979-836-1212 |